Crucell CEO Dr. Dinko Valerio Talks to the Wall Street Transcript.Business Editors NEW YORK--(BUSINESS WIRE)--Oct. 3, 2003 The Wall Street Transcript A generic term for any kind of copy, particularly an official or certified representation of the record of what took place in a court during a trial or other legal proceeding. A transcript of record has published an in-depth interview with Dr. Dinko Valerio of Crucell NV (Nasdaq:CRXL) (Euronext:CRXL) in which he talks at length about the Company's vaccine vaccine Preparation containing either killed or weakened live microorganisms or their toxins, introduced by mouth, by injection, or by nasal spray to stimulate production of antibodies against an infectious agent. development programs and its goals for the future. The entire 2,500 word interview is available free online at http://www.twst.com/ceos.htm. Crucell NV is a Netherlands based-biotechnology company that develops products to combat infectious diseases infectious diseases: see communicable diseases. . The Company has a wide range of vaccines in development including vaccines for the flu, West Nile West Nile may refer to:
In describing the Company's current partnerships, Dr. Valerio states, "We have a wide range of partnerships in place. For example, Merck & Co. is using our technology in order to further develop an AIDS vaccine AIDS vaccine A hypothetical vaccine intended to either prevent HIV infection or ensure that those infected will not fall victim to AIDS; the most promising vaccine is that using a naked DNA plasmid, reported by Letwin et al in 20/10/00 Science; as of early 2001, . That is a very important partnership for us. Merck has exclusive rights to the technology in this particular area, and Crucell is being paid for that both in annual fees, milestone payments and royalties from net sales Net Sales The amount a seller receives from the buyer after costs associated with the sale are deducted. Notes: This amount is calculated by subtracting the following items from gross sales: merchandise returned for credit, allowances for damaged or missing goods, freight of the AIDS vaccine once it enters the marketplace." Regarding current developments, Dr. Valerio states, "The Ebola virus vaccine, which we are developing together with the National Institutes of Health and the U.S. Army, is in the pre-clinical phase. We expect that by the end of the year we will have all the necessary experiments done, allowing us to prepare for a clinical trial that is expected to start at the end of 2004." The Wall Street Transcript does not endorse the views of any interviewees nor does it make stock recommendations. For subscription information call 800-246-7673. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion